Patient eligibility
bleeding, allergy, irritations
RECRUITMENT, BLEEDING, ALLERGY, RECRUITMENT, MAY, CAVITY, ALBERT
Between April 2021 and May 2021, COVID-19 inpatients at the Hospital Israelita Albert Einstein (HIAE) were considered for participation in this investigation. The study was registered at clinicaltrials.gov (NCT04902976) in May 2021. Recruitment was initiated in April 2021 after HIAE Ethical Committee approval (43550721.4.0000.0071). The study was initiated before it was registered at clinicaltrials.gov due to the difficulties in recruiting the total number of patients needed during the COVID-19 pandemic and the oscillations of hospitalizations during this period.The inclusion criteria were age 18 to 90 years old; up to 3 days of hospitalization length and a maximum of 7 days from first symptom appearance; positivity for SARS-CoV-2 as determined by reverse transcription-polymerase chain reaction (RT–PCR) performed in nasopharyngeal samples; positivity for SARS-CoV-2 in the first collection of saliva samples; and needing oral hygiene guidance and other preventive and therapeutic oral care. The exclusion criteria were absence of SARS-CoV-2 positivity detected by RT–PCR at the time of recruitment or at the time of the first saliva collection; oral lesions that contraindicated the use of cetylpyridinium chloride mouthwash; pregnant and breastfeeding women; bleeding in the oral cavity; allergy, irritations or other side effects derived from use of the intervention solutions; exposure to intervention solutions or other antimicrobial agents 48 h before the baseline collection; disagreement with the protocol or inadequate intervention performance by the patient.